cetirizine + chlorpheniramine + methylprednisolone

This combination therapeutic regimen was utilized as the conventional treatment arm in a Phase 2 clinical trial conducted by the National Polytechnic Institute (IPN) in Mexico for pediatric patients with moderate atopic dermatitis. The regimen consists of two systemic antihistamines—cetirizine (a second-generation H1 antagonist) and chlorpheniramine (a first-generation H1 antagonist)—alongside a topical corticosteroid, methylprednisolone aceponate 0.1%. This combination aims to manage the pruritus and inflammatory skin lesions associated with atopic dermatitis. In the specific trial context, it served as the standard-of-care comparator against which the efficacy of Transferon (Dialyzed Leukocyte Extracts) was measured as an adjuvant therapy.

Other names

conventional treatment (National Polytechnic Institute, Mexico)standard treatment for atopic dermatitis (IPN study)